Loading clinical trials...

NOT_YET_RECRUITINGNA

Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

Pralatrexate Combined With Chidamide Bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed Peripheral T-cell Lymphoma

NCT06671717•Peking University People's Hospital

View on ClinicalTrials.gov

Summary

This is a multicenter, prospective study of Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed Peripheral T-cell Lymphoma

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients fully understand the study, voluntarily participate in and sign on the informed consent;
•Diagnosed by histopathology Peripheral T-cell lymphoma;
•ECOG PS score 0 or 1;
•Relapsed or Refractory Peripheral T Cell Lymphoma；
•According to the 2014 version of the Lugano criteria for lymphoma, there must be at least one CT/MRI measurable lesion (measurable lymph node diameter\>1.5cm; measurable extranodal lesion diameter\>1.0cm)；
•Provided a written pathological/histological diagnosis report during the screening period and agreed to provide tumor tissue sections or tumor/lymph node tissue specimens for testing at the central laboratory;
•Expected survival at least 12 weeks；
•Agreed to receive treatment with Pralatrexate

Exclusion Criteria

•NK/T-cell lymphoma;
•Achieving CR or PR after induction chemotherapies without relapse;
•Dysfunction of vital organs;
•Serious history of autoimmune diseases and immunodeficiency, including: positive for human immunodeficiency virus (HIV) antibodies; Or other acquired or congenital immunodeficiency diseases; Or have a history of organ transplantation;
•Unwilling to accept allogeneic hematopoietic stem cell transplantation;
•Undergoing other clinical studies within a month;
•Without donor for transplantation;
•Allergies to similar drugs and excipients of the research drug

Locations (1)

Peking University, Institute of Hematolgoy, Beijing,

Beijing, China

Key Dates

Start Date

December 1, 2024

Primary Completion Date

April 1, 2027

Completion Date

July 1, 2027

Last Updated

November 6, 2024

Enrollment

ESTIMATED participants

Conditions

Relapsed Peripheral T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma

Interventions

Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation

OTHER

Contacts

Xiaodong Mo, MD

CONTACT

8610-8832-6001 mxd453@163.com

Xiaodong Mo, MD

CONTACT

8610-8832-4577 mxd453@163.com

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

NCT06909877

Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

View study

RECRUITINGPHASE2

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

NCT05833724

Relapsed or Refractory Peripheral T-cell Lymphoma

View study

RECRUITINGPHASE1/PHASE2

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 6, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

Inclusion Criteria

Exclusion Criteria

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin